Biotechnology company Intrexon Corp. has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $125 million in an initial public offering of common stock. The company did not specify the number of shares to be sold and the price range for the proposed offering.
The Germantown, Maryland based company plans to list on the New York Stock Exchange under the ticker symbol XON.
The company said in a preliminary prospectus that it plans to use the proceeds to fund continued investment in research and development platforms and its business development efforts.
Intrexon is a leader in the field of synthetic biology, an emerging and rapidly evolving discipline that applies engineering principles to biological systems
Intrexon, which was founded in 1998, is now controlled by Randal Kirk, who has been the chief executive of the company since 2005.
J.P. Morgan and Barclays are the joint bookrunners on the deal.
Click here to receive FREE breaking news email alerts for Intrexon Corporation and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org